COMMUNIQUÉ DE PRESSE publié le 30/08/2023 à 14:30, il y a 2 années 8 mois The Science Times Publishes Article About Jaguar Health's Focus on Developing Crofelemer for Two Rare Disease Indications
COMMUNIQUÉ DE PRESSE publié le 28/08/2023 à 14:30, il y a 2 années 8 mois Jaguar Health to Present September 7 at Emerging Growth Conference and at the September 11-13 H.C. Wainwright Annual Global Investment Conference
COMMUNIQUÉ DE PRESSE publié le 24/08/2023 à 13:00, il y a 2 années 8 mois Jaguar Health Engages B2i Digital to Deploy Cutting-Edge Investor Engagement Campaign
COMMUNIQUÉ DE PRESSE publié le 17/08/2023 à 14:30, il y a 2 années 8 mois Napo Pharmaceuticals, a Jaguar Health Family Company, Reports Completion of Last Patient Last Visit for its Pivotal Phase 3 OnTarget Trial of Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea
COMMUNIQUÉ DE PRESSE publié le 16/08/2023 à 14:30, il y a 2 années 8 mois Napo Pharmaceuticals Surveys of Neurologists, Patients, and Caregivers Regarding Amyotrophic Lateral Sclerosis (ALS) Treatment Indicate Real World Burden of Diarrhea and Potential Treatment Interruption
COMMUNIQUÉ DE PRESSE publié le 14/08/2023 à 14:00, il y a 2 années 8 mois Jaguar Health Reports Second Quarter 2023 Financial Results
COMMUNIQUÉ DE PRESSE publié le 10/08/2023 à 14:30, il y a 2 années 9 mois Jaguar Health to Hold Investor Webcast Monday, August 14th at 8:30 AM EDT Regarding Q2 2023 Financials & Corporate Updates
COMMUNIQUÉ DE PRESSE publié le 09/08/2023 à 14:30, il y a 2 années 9 mois Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to BARDA for Development of NP-300 Drug Candidate for Cholera-Related Diarrhea
COMMUNIQUÉ DE PRESSE publié le 08/08/2023 à 14:30, il y a 2 années 9 mois Napo Pharmaceuticals, a Jaguar Health Company, Announces Activation by FDA of Investigational New Drug (IND) Application for Crofelemer for Treatment of Microvillus Inclusion Disease
COMMUNIQUÉ DE PRESSE publié le 07/08/2023 à 14:30, il y a 2 années 9 mois Independent Study Published in Clinical Breast Cancer Shows Activity of Jaguar Health's Crofelemer for Neratinib-induced Diarrhea
Publié le 07/05/2026 à 19:15, il y a 2 jours 19 heures 2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Publié le 07/05/2026 à 19:15, il y a 2 jours 19 heures Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Publié le 07/05/2026 à 19:06, il y a 2 jours 19 heures Disclosure of Share Capital and Voting Rights as of April 30, 2026
Publié le 07/05/2026 à 19:06, il y a 2 jours 19 heures Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Publié le 07/05/2026 à 19:00, il y a 2 jours 19 heures ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Publié le 09/05/2026 à 01:30, il y a 1 jour 13 heures Star Copper Announces Agreement with Zimtu Capital Corp.
Publié le 09/05/2026 à 00:00, il y a 1 jour 14 heures Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Publié le 10/05/2026 à 14:00, il y a 48 minutes MBC GROUP DELIVERS RESILIENT 1Q 2026 PERFORMANCE ANCHORED BY STRONG MBC SHAHID GROWTH
Publié le 10/05/2026 à 11:45, il y a 3 heures 3 minutes Hisense Kicks Off FIFA World Cup 2026™ Campaign, Bringing Fans Closer Through "Innovating a Brighter Life"
Publié le 09/05/2026 à 19:05, il y a 19 heures 43 minutes LONGi EcoLife Series Module Top TaiyangNews Global Ranking, Ushering in the "25%+" Era of Photovoltaic Efficiency
Publié le 08/05/2026 à 20:38, il y a 1 jour 18 heures EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Publié le 08/05/2026 à 19:12, il y a 1 jour 19 heures EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026
